Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GB-5267 |
| Synonyms | |
| Therapy Description |
GB-5267 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting MUC16 linked to a co-stimulatory 4-1BB domain and TCR/CD3zeta and expressing IL18, which potentially induces antitumor immune response (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GB-5267 | GB5267|GB 5267 | MUC16 Targeted Therapy 12 | GB-5267 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting MUC16 linked to a co-stimulatory 4-1BB domain and TCR/CD3zeta and expressing IL18, which potentially induces antitumor immune response (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07489287 | Phase I | GB-5267 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | Recruiting | USA | 0 |